Physician profile
Syeda Khan
NPI 1366639221
$1,976.81
in general payments reported to CMS, 2019-2025
19 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.56 · 2022: $232 · 2023: $392 · 2024: $812 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.58 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $307.91 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $259.42 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $138.60 | 2024-2025 | |
| Sight Sciences, INC. | $124.98 | 2022 | |
| Abbvie INC. | $124.20 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.40 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $101.13 | 2024-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $94.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $64.05 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $61.87 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $53.58 | 2024 | Rexulti |
| Astellas Pharma US INC | $42.06 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $35.33 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $23.05 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.98 | 2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $20.10 | 2024 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $19.61 | 2025 | Uptravi, Opsumit |
| Idorsia Pharmaceuticals US INC | $15.51 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syeda Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.